Focus:
Shanghai Green Valley Pharmaceuticals’ new Alzheimer’s disease drug, Oligomannate, has been conditionally approved in China and became available for purchase in late December. This is the first novel Alzheimer’s disease...
In the 7MM (US, France, Germany, Italy, Spain, the UK, and Japan), of the most diagnosed incident cases of ovarian cancer are initially diagnosed in stage III. A diagnosis of...
On December 18, a federal appeals court decided to strike down the Affordable Care Act's (ACA) individual mandate, which necessitates individuals to maintain healthcare coverage or otherwise pay a fee...
In 2018, GEDmatch was used by US authorities to identify and arrest the alleged Golden State Killer.
Sanofi is aiming to pivot away from its struggling diabetes and cardiovascular R&D programmes in order to save $2bn over the next few years and focus on its oncology and...
Manufacturing impurities and FDA and EMA recalls have become a recurrent and worrying trend.
Sarepta Therapeutics’ Vyondys 53 has been approved to treat patients with a rare disease, Duchenne muscular dystrophy (DMD).
The new change in BMS’ approach with relatlimab is set to give the company an advantage in the IO market by making it the first to market across multiple indications.
The IL-15 receptor plays a very important role in the immune system by affecting the maintenance, function, and development of natural killer and T- cells.
Diabetes sales will continue to dominate metabolic disorders space.
